We present the discovery and the subsequent follow up of radio emission from SDSS J130402.36+293840.6 (J1304+2938), the candidate host galaxy of the gamma-ray burst (GRB) GRB 200716C. The galaxy is ...detected in the RACS (0.89 GHz), the NVSS, the Apertif imaging survey, and the FIRST (1.4 GHz), the VLASS (3 GHz), and in public LOFAR (130–170 MHz), WISE (3.4–22 μm), and SDSS (
z
,
i
,
r
,
g
,
u
filters) data. The luminosity inferred at 1.4 GHz is (5.1 ± 0.2) × 10
30
erg s
−1
Hz
−1
. To characterise the emission and distinguish between different components within the galaxy, we performed dedicated, high-sensitivity and high-resolution observations with the European VLBI Network (EVN) +
e
-MERLIN at 1.6 and 5 GHz. We did not detect any emission from a compact core, suggesting that the presence of a radio-loud active galactic nucleus (AGN) is unlikely, and therefore we ascribe the emission observed in the public surveys to star-forming regions within the galaxy. We confirm and refine the redshift estimate,
z
= 0.341 ± 0.004, with a dedicated Telescopio Nazionale
Galileo
(TNG) spectroscopic observation. Finally, we compiled a list of all the known hosts of GRB afterglows detected in radio and computed the corresponding radio luminosity: if GRB 200716C belongs to J1304+2938, this is the third most radio-luminous host of a GRB, implying one of the highest star-formation rates (SFRs) currently known, namely SFR ∼ 324±61
M
⊙
yr
−1
. On the other hand, through the analysis of the prompt emission light curve, recent works suggest that GRB 200716C might be a short-duration GRB located beyond J1304+2938 and gravitationally lensed by an intermediate-mass black hole (IMBH) hosted by the galaxy. Neither the public data nor our Very Long Baseline Interferometry (VLBI) observations can confirm or rule out the presence of an IMBH acting as a (milli-)lens hosted by the galaxy, a scenario still compatible with the set of radio observations presented in this work.
The Lancet Respiratory Medicine Commission on drug-resistant tuberculosis was published in 2017, which comprehensively reviewed and provided recommendations on various aspects of the disease. Several ...key new developments regarding drug-resistant tuberculosis are outlined in this Commission Update. The WHO guidelines on treating drug-resistant tuberculosis were updated in 2019 with a reclassification of second line anti-tuberculosis drugs. An injection-free MDR tuberculosis treatment regimen is now recommended. Over the past 3 years, advances in treatment include the recognition of the safety and mortality benefit of bedaquiline, the finding that the 9-11 month injectable-based 'Bangladesh' regimen was non-inferior to longer regimens, and promising interim results of a novel 6 month 3-drug regimen (bedaquiline, pretomanid, and linezolid). Studies of explanted lungs from patients with drug-resistant tuberculosis have shown substantial drug-specific gradients across pulmonary cavities, suggesting that alternative dosing and drug delivery strategies are needed to reduce functional monotherapy at the site of disease. Several controversies are discussed including the optimal route of drug administration, optimal number of drugs constituting a regimen, selection of individual drugs for a regimen, duration of the regimen, and minimal desirable standards of antibiotic stewardship. Newer rapid nucleic acid amplification test platforms, including point-of-care systems that facilitate active case-finding, are discussed. The rapid diagnosis of resistance to other drugs, (notably fluoroquinolones), and detection of resistance by targeted or whole genome sequencing will probably change the diagnostic landscape in the near future.
Infectious diseases, such as tuberculosis (TB) and the novel coronavirus (COVID-19) relate to environmental factors, understanding of which is essential to inform policy and practice and tackle them ...effectively.
The review follows the conceptual framework offered by the World Health Organization Commission on Social Determinants of Health (defined as “all those material, psychological and behavioural circumstances linked to health and generically indicated as risk factors’ in the conventional epidemiological language”). It describes the social factors behind TB and COVID-19, the commonalities between the two diseases, and what can be learned so far from the published best practices.
The social determinants sustaining TB and COVID-19 underline the importance of prioritising health and allocating adequate financial and human resources to achieve universal health coverage and health-related social protection while addressing the needs of vulnerable populations. Rapid and effective measures against poverty and other major social determinants and sources of inequality are urgently needed to develop better health in the post-COVID-19 world.
AbstractThe goals of the End TB strategy, which aims to achieve a 90% reduction in tuberculosis (TB) incidence and a 95% reduction in TB mortality by 2035, will not be achieved without new tools to ...fight TB. These include improved point of care (POC) diagnostic tests that are meant to be delivered at the most decentralised levels of care where the patients make the initial contact with the health system, as well as within the community. These tests should be able to be performed on an easily accessible sample and provide results in a timely manner, allowing a quick treatment turnaround time of a few minutes or hours (in a single clinical encounter), hence avoiding patient loss-to-follow-up. There have been exciting developments in recent years, including the WHO endorsement of Xpert MTB/RIF, Xpert MTB/RIF Ultra, loop-mediated isothermal amplification (TB-LAMP) and lateral flow lipoarabinomannan (LAM). However, these tests have limitations that must be overcome before they can be optimally applied at the POC. Furthermore, worrying short- to medium-term gaps exist in the POC diagnostic test development pipeline. Thus, not only is better implementation of existing tools and algorithms needed, but new research is required to develop new POC tests that allow the TB community to truly make an impact and find the “missed TB cases”.
BACKGROUND: The aim of these clinical standards is to provide guidance on 'best practice´ for diagnosis, treatment and management of drug-susceptible pulmonary TB (PTB).METHODS: A panel of 54 global ...experts in the field of TB care, public health, microbiology,
and pharmacology were identified; 46 participated in a Delphi process. A 5-point Likert scale was used to score draft standards. The final document represents the broad consensus and was approved by all 46 participants.RESULTS: Seven clinical standards were defined: Standard 1,
all patients (adult or child) who have symptoms and signs compatible with PTB should undergo investigations to reach a diagnosis; Standard 2, adequate bacteriological tests should be conducted to exclude drug-resistant TB; Standard 3, an appropriate regimen recommended by WHO and national
guidelines for the treatment of PTB should be identified; Standard 4, health education and counselling should be provided for each patient starting treatment; Standard 5, treatment monitoring should be conducted to assess adherence, follow patient progress, identify and manage adverse events,
and detect development of resistance; Standard 6, a recommended series of patient examinations should be performed at the end of treatment; Standard 7, necessary public health actions should be conducted for each patient. We also identified priorities for future research into PTB.CONCLUSION:
These consensus-based clinical standards will help to improve patient care by guiding clinicians and programme managers in planning and implementation of locally appropriate measures for optimal person-centred treatment for PTB.
ABSTRACT
We present the first X-ray observation at sub-arcsecond resolution of the high-redshift (z = 6.18) radio-loud quasar CFHQS J142952 + 544717 (J1429). The ∼100 net-count 0.3–7 keV spectrum ...obtained from ∼30 ks Chandra exposure is best fit by a single power-law model with a photon index Γ = 2.0 ± 0.2 and no indication of an intrinsic absorber, implying a 3.6–72 keV rest-frame luminosity $L_{\rm X}=(2.3^{+0.6}_{-0.5})\times 10^{46}$ erg s−1. We identify a second X-ray source at 30″ distance from J1429 position, with a soft (Γ ≃ 2.8) and absorbed (equivalent hydrogen column density NH < 13.4 × 1020 cm−2) spectrum, which likely contaminated J1429 spectra obtained in lower angular resolution observations. Based on the analysis of the Chandra image, the bulk of the X-ray luminosity is produced within the central ∼3 kpc region, either by the disc/corona system, or by a moderately aligned jet. In this context, we discuss the source properties in comparison with samples of low- and high-redshift quasars. We find indication of a possible excess of counts over the expectations for a point-like source in a 0.5″–1.5″ (∼3−8 kpc) annular region. The corresponding X-ray luminosity at J1429 redshift is 4 × 1045 erg s−1. If confirmed, this emission could be related to either a large-scale X-ray jet, or a separate X-ray source.
ABSTRACT We report the γ-ray detection of a young radio galaxy, PKS 1718−649, belonging to the class of compact symmetric objects (CSOs), with the Large Area Telescope (LAT) on board the Fermi ...satellite. The third Fermi Gamma-ray LAT catalog (3FGL) includes an unassociated γ-ray source, 3FGL J1728.0−6446, located close to PKS 1718−649. Using the latest Pass 8 calibration, we confirm that the best-fit 1 position of the γ-ray source is compatible with the radio location of PKS 1718−649. Cross-matching of the γ-ray source position with the positions of blazar sources from several catalogs yields negative results. Thus, we conclude that PKS 1718−649 is the most likely counterpart to the unassociated LAT source. We obtain a detection test statistics TS ∼ 36 (>5 ) with a best-fit photon spectral index Γ = 2.9 0.3 and a 0.1-100 GeV photon flux density F0.1−100 GeV = (11.5 0.3) × 10−9 ph cm−2 s−1. We argue that the linear size (∼2 pc), the kinematic age (∼100 years), and the source distance (z = 0.014) make PKS 1718−649 an ideal candidate for γ-ray detection in the framework of the model proposing that the most compact and the youngest CSOs can efficiently produce GeV radiation via inverse-Compton scattering of the ambient photon fields by the radio lobe non-thermal electrons. Thus, our detection of the source in γ-rays establishes young radio galaxies as a distinct class of extragalactic high-energy emitters and yields a unique insight on the physical conditions in compact radio lobes interacting with the interstellar medium of the host galaxy.
PDF
